CureVac’s Defining Moment: Shareholders to Decide Company’s Fate

The future of Tübingen-based biotech firm CureVac hangs in the balance as the company approaches a critical juncture. With operational performance weakening, shareholders face a landmark decision that will determine whether the company maintains its independence or becomes part of competitor BioNTech.

Shareholder Vote to Determine Acquisition Outcome

All eyes are fixed on tomorrow’s extraordinary general meeting scheduled for Tuesday, November 25, 2025. During this session, investors will cast their votes on resolutions necessary to advance the proposed transaction with BioNTech. Their approval represents the final hurdle before the public exchange offer can proceed, effectively deciding whether CureVac continues operating as an independent entity.

Strategic Rationale Behind mRNA Merger

BioNTech’s public acquisition offer remains open until December 3, 2025. The strategic logic centers on combining the complementary mRNA technology platforms of both companies. The stated objective involves accelerating development of innovative cancer treatments. Investors have been presented with specific terms valuing each CureVac share at approximately $5.46, payable in BioNTech stock.

Should investors sell immediately? Or is it worth buying CureVac?

Financial Performance Underscores Strategic Imperative

Recent financial results highlight the transaction’s strategic importance. Just before the decisive meeting, CureVac disclosed third-quarter figures revealing a clear pattern of declining revenues and profits compared to the same period last year.

This financial pressure has intensified the management’s position while providing context for the ongoing acquisition talks. Market tension is evident in the current share price of €4.42, which trades below the proposed offer value, reflecting investor anxiety ahead of the vote. The financial community now awaits tomorrow’s outcome, which will ultimately determine CureVac’s trajectory.